Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: lrb who wrote (648)	2/11/1998 3:00:00 PM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

<< Anyone been to one of them-there "investor breakfasts" lately.?>> Not an investor breakfast but I did just listen in on one of them-there conference calls. IMO, the three things that you are interested in are the keys to changing public perception of MGI Pharma. Whether it will take one, two or all three things to happen to change that perception, we'll have to wait and see. Some of the below comments are from the conference call, some are from that-there breakfast last December: >> They are still at 14.15mg/m^2 dose level in phase I. They think is about the MTD for typical phase I patients that have advanced cancer and have already experienced extensive cancer treatments. They expect the MTD of patients that are not so weakened to be a little higher. They remain very optimistic about the value of MGI-114 and the moving into phase II. If the results from the lab are any guide, the effectiveness of this drug will be dramatically different when the tumors are not so large and extensive. >> They applied for Salagen/Sjogren's approval exactly one year ago today. Approval can take up to two years but they typically come much quicker when there is no alternative treatment for an indication (as is the case for Sjogren's). They expect approval very soon. >> They are presently active in negotiations with several companies for a European partner for MGI-114. Nothing was mentioned about "winter" vacations. :-) They fully expect this deal to be realized and expect it to happen slightly before or slightly after the beginning of phase II trials. I was hoping for slightly better numbers today but the trend still looks very good. The market has reacted with a yawn and will likely continue to do so until the things you are interested in become realized. I'm looking forward to phase II, the NCI involvement and disappearing tumors. David